Tilray Brands, Inc.
HealthcareNASDAQ:TLRY · NASDAQ Global Select
-$0.14 today
Vol 3.14M · Avg 4.67M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$3.0B -798.9% | -$333.8M +82.9% | -$2.0B -225.5% | -$601.0M -35.5% | -$443.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $183.2M +5.9% | $172.9M -1.4% | $175.3M -10.0% | $194.9M +137.9% | $81.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$166.1M -213.5% | -$53.0M -23.1% | -$43.0M -24.0% | -$34.7M -15.6% | -$30.0M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 | $0 | $0 | $0 | $0 | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$85.8M -610.2% | -$12.1M -162.3% | $19.4M +116.8% | -$115.7M -88.1% | -$61.5M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$24.4M -172.6% | -$9.0M -259.6% | $5.6M +176.2% | -$7.4M +74.1% | -$28.4M | $592.6M | $1.3B | $626.2M |
| Inventory | -$18.6M +12.3% | -$21.2M -21.8% | -$17.4M +69.8% | -$57.7M -35.4% | -$42.6M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$31.5M -10996.2% | $288.9K -98.9% | $27.0M +148.0% | -$56.3M -421.5% | $17.5M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$11.3M -163.7% | $17.8M +323.5% | $4.2M -25.4% | $5.6M +170.3% | -$8.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $2.9B +1499.1% | $183.8M -89.9% | $1.8B +445.1% | $333.1M -16.6% | $399.3M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$129.8M -208.3% | -$42.1M -495.4% | $10.6M +104.8% | -$223.5M -313.9% | -$54.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$45.2M -13.3% | -$39.9M -42.2% | -$28.0M +34.8% | -$42.9M +8.5% | -$46.9M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$15.5M +78.2% | -$71.0M -135.2% | -$30.2M -291.1% | $15.8M -82.1% | $88.4M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$3.5M | $0 +100.0% | -$325.8M | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 -100.0% | $285.8M | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 -100.0% | $14.2M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$64.1M -136.7% | $174.9M +145.5% | -$384.0M -1314.8% | -$27.1M -148.8% | $55.7M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$31.9M +71.1% | -$110.2M -43.3% | -$77.0M +48.6% | -$149.9M -366.5% | $56.2M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $221.2M +1783.4% | $11.7M -93.3% | $174.6M -47.2% | $330.9M +166.9% | $124.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 +100.0% | -$1.6M | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$6.1M -54.3% | -$4.0M -163.3% | -$1.5M +92.3% | -$19.5M +35.4% | -$30.1M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $183.2M +278.8% | -$102.4M -208.4% | $94.5M -41.5% | $161.6M +7.7% | $150.1M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $1.6M +308.6% | -$748.0K +75.1% | -$3.0M -21.7% | -$2.5M -100.8% | $321.1M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$9.2M -131.0% | $29.6M +110.5% | -$281.9M -208.2% | -$91.5M -119.3% | $472.9M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$175.0M -113.5% | -$82.0M -371.9% | -$17.4M +93.5% | -$266.4M -163.9% | -$100.9M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Neogen Corporation
NASDAQ:NEOG
$1.98B
Dynavax Technologies Corporation
DVAX
$1.82B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Alvotech
NASDAQ:ALVO
$1.30B
Phibro Animal Health Corporation
NASDAQ:PAHC
$1.28B
Evotec SE
NASDAQ:EVO
$966.11M
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
SEC Filings
Recent regulatory filings
No filings found.
Does TLRY generate free cash flow?
Tilray Brands, Inc. (TLRY) generated -$174,976,180.00 of free cash flow in fiscal 2025.
How much operating cash flow does TLRY produce?
Operating cash flow was -$129,807,801.00, before capital expenditures of $45.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.